The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

In trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit offers insight into the new NCCN guidelines, discusses the new ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

The tool predicts which of two standard front-line chemotherapy options a patient with advanced pancreatic cancer is likely to benefit from.